RE: Unless21 Oct 2024 16:43
No stocky read the rns first, the 10m is now or imminent when deal closed (initial consideration), you are talking about the 50m ..
A summary of the agreed commercial terms in the term sheet are listed below:
· Initial consideration value of US$10 million, which includes non-dilutive equity in the SPV;
· Exclusive worldwide licence granted to the SPV for 20 years;
· Within 3 years, PDC to develop at least one of the Midkine antibodies within the SPV to the completion of a Phase 1 trial and then, upon success, to complete a trade sale of the SPV; and
· Roquefort Therapeutics will receive circa 24% from any successful trade sale proceeds, which if the Phase 1 trial is successful, this 24% is projected to be worth up to US$50M (gross) based on similar phase 1 trade sales.